New Perspectives for Adjuvant Therapy in Severe MalariaMauro Prato1,2*, Giuliana Giribaldi1
- *Corresponding Author:
- Prof. Mauro Prato
Dipartimento di Genetica, Biologia e Biochimica
Facoltà di Medicina e Chirurgia
Università degli studi di Torino
Via Santena 5 bis, 10126, Torino, Italy
Fax: +39-011-670-58- 45
Email: [email protected]
Received date: April 02, 2012; Accepted date: April 03, 2012; Published date: April 09, 2012
Citation: Prato M, Giribaldi G (2012) New Perspectives for Adjuvant Therapy in Severe Malaria. J Bacteriol Parasitol 3:e105. doi: 10.4172/2155-9597.1000e105
Copyright: ©2012 Prato M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Malaria is one of the most common parasitic diseases in the world, leading to over 1 million deaths/year. It mainly affects children under 5 years of age and pregnant women and can be fatal. The most virulent among the human malaria parasites is Plasmodium falciparum (Pf), which is responsible for the bulk of the malaria-related morbidity and mortality. Symptoms of uncomplicated malaria include fever, headache and vomiting, whereas the major complications of severe malaria include Cerebral Malaria (CM), pulmonary edema, acute renal failure or severe anaemia. It is characterized by the binding of Infected Red Blood Cell (IRBC) to the vascular endothelium (cytoadherence) and to non-infected erythrocytes (rosetting). The accumulation of IRBC and non-infected RBC generates a reduction in the blood flow of the microvasculature, which results in tissue hypoxia and necrosis.